Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3526318 single- and multiple-ascending dose safety and pharmacokinetics study in healthy volunteers
NL-OMON48109Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3526318 in chronic pain, sponsored by Eli Lilly and Company. Primary endpoint: Adverse events and serious adverse events. Started Jun 2019; status: active, not recruiting.
02
Drugs
LY3526318
03
Conditions
chronic pain
Beyond the preview
Go deeper on NL-OMON48109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48109.